Jump to main content
eTG Complete
eTG Complete
Index
  1. Home
  2. Antibiotic
  3. Skin and soft tissue infections
  4. Cellulitis and erysipelas
  5. Empirical therapy for cellulitis and erysipelas without systemic features
  • Antibiotic
    • Bartonella infections
    • Osteomyelitis
    • Septic arthritis of a native joint
    • Bone and joint infections other than osteomyelitis and native joint septic arthritis
    • Sepsis or septic shock associated with a bone or joint source
    • Directed therapy for native bone or joint infection
    • Brucellosis
    • Infective endocarditis
    • Cardiovascular system infections other than endocarditis
    • Central nervous system infections
    • Coronavirus disease 2019 (COVID-19)
    • Cryptococcosis
    • Cytomegalovirus (CMV) infection
    • Infectious diarrhoea
    • Ear, nose and throat infections
    • Eye infections
    • Febrile neutropenia
    • Genital and sexually transmissible infections
    • Human immunodeficiency virus
    • Intra-abdominal infections
    • Leptospirosis
    • Lyme disease
    • Mediastinitis
    • Melioidosis
    • Mpox (monkeypox)
    • Nocardiosis
    • Nontuberculous mycobacterial infections
    • Oesophageal infections
    • Parasitic infections
    • Perinatal infections
    • Prevention of infection
    • Q fever
    • Pneumonia
    • Directed therapy for pneumonia
    • Respiratory tract infections other than pneumonia
    • Acute rheumatic fever
    • Rickettsial infections
    • Salivary gland infections
    • Sepsis and septic shock: Identification and initial management
    • Sepsis and septic shock: Empirical regimens
    • Directed therapy for bloodstream infections, including sepsis and septic shock
    • Skin and soft tissue infections
      • Boils and carbuncles
      • Cellulitis and erysipelas
        • Assessment of cellulitis and erysipelas
        • Aetiology of cellulitis and erysipelas
        • Management of cellulitis and erysipelas
        • Empirical therapy for cellulitis and erysipelas without systemic features
          • Patients with cellulitis or erysipelas without systemic features who are at low risk of MRSA infection
          • Patients with cellulitis or erysipelas without systemic features who are at increased risk of MRSA infection
          • Patient review, and modification and duration of therapy for cellulitis or erysipelas without systemic features
        • Empirical therapy for cellulitis and erysipelas with systemic features
        • Empirical therapy for cellulitis associated with hypotension, septic shock, severe pain, or rapid progression of systemic features or erythema
        • Preventing recurrent cellulitis
        • References
      • Chickenpox (varicella)
      • Infections of chronic ulcers and wounds
      • Infections of diabetes-related foot ulcers
      • Impetigo
      • Lactational mastitis
      • Necrotising skin and soft tissue infections
      • Recurrent staphylococcal skin infection
      • Shingles (herpes zoster)
      • Staphylococcal scalded skin syndrome
      • Surgical site infections
    • Traumatic wound infections
    • Urinary tract infections in adults
    • Urinary tract infections in children
    • Identifying resistant pathogens or Candida species
    • Principles of obtaining blood for culture
    • Principles of antimicrobial use
    • Antimicrobial stewardship (AMS)
    • Practical information on using antimicrobial drugs
    • Aminoglycoside use
    • Vancomycin use in adults
    • Vancomycin use in young infants and children
    • Monitoring antimicrobial blood concentrations
    • Ambulatory antimicrobial therapy
    • Antimicrobial hypersensitivity
    • Kidney impairment and antimicrobial dosing
    • Contact details for health departments and public health units
    • Amikacin initial dose calculator
    • Gentamicin initial dose calculator
    • Tobramycin initial dose calculator

Empirical therapy for cellulitis and erysipelas without systemic features

For patients with periorbital (preseptal) or orbital (postseptal) cellulitis, see Approach to managing periorbital (preseptal) cellulitis or Approach to managing orbital (postseptal) cellulitis.

  • Patients with cellulitis or erysipelas without systemic features who are at low risk of MRSA infection
  • Patients with cellulitis or erysipelas without systemic features who are at increased risk of MRSA infection
  • Patient review, and modification and duration of therapy for cellulitis or erysipelas without systemic features
  • Contact us
  • Conditions of use and disclaimer
  • Privacy policy
  • Copyright permission
  • Support and FAQ

www.tg.org.au
All site content © Therapeutic Guidelines Limited 2020. Therapeutic Guidelines Limited, Ground Floor, 473 Victoria Street, West Melbourne, Victoria 3003, Australia © Therapeutic Guidelines Ltd (eTG August 2020)

Created: No created attribute found. Modified: No revised attribute found. (HW Diagnostics)